Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 12/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31347248 | 0.82 | F10 (0.48) | JAK2JAK1JAK3TYK2F10 | |
| SCHEMBL1028503 | 0.82 | F10 (0.48) | JAK2JAK1JAK3TYK2F10 | |
| SCHEMBL5830580 | 0.82 | DGAT1 (0.46) | F10DGAT1LRRK2 | |
| SCHEMBL4639953 | 0.81 | PIK3CD (0.46) | JAK2JAK1JAK3TYK2F10 | |
| SCHEMBL24195918 | 0.79 | F10 (0.48) | JAK2JAK1JAK3TYK2F10 | |
| SCHEMBL28190265 | 0.79 | PRKDC (0.55) | JAK2JAK1JAK3TYK2DGAT1 | |
| SCHEMBL4101204 | 0.78 | ALDH1A1 (0.47) | F10DGAT1LRRK2 | |
| SCHEMBL5442375 | 0.78 | F10 (0.47) | JAK2JAK1JAK3TYK2F10 | |
| SCHEMBL8262171 | 0.78 | F10 (0.45) | JAK2JAK1JAK3TYK2F10 | |
| SCHEMBL8305482 | 0.78 | F10 (0.47) | F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718679-B2 | Heteroaryl carboxamides | HOFFMAN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | claimed |
| EP-2076511-A1 | NOVEL HETEROARYL CARBOXAMIDES | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | claimed |
| WO-2008049747-A1 | NOVEL HETEROARYL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-02 | — | — | WO | claimed |
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | claimed |
| US-7718679-B2 | Heteroaryl carboxamides | HOFFMAN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| EP-2076511-A1 | NOVEL HETEROARYL CARBOXAMIDES | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008049747-A1 | NOVEL HETEROARYL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-02 | — | — | WO | disclosed |
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| EP-1877404-A2 | NOVEL CYCLIC AMINES | F. Hoffmann-Roche AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006114401-A2 | NOVEL CYCLIC AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | F12, F11, F2 | JAK2 123/4885JAK1 589/4885JAK3 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.